Below is a detailed analysis of the quarterly data for Blue Jet Healthcare Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
For Sales, as of Mar 2025, the value is 340.00 Cr.. The value appears strong and on an upward trend. It has increased from 318.00 Cr. (Dec 2024) to 340.00 Cr., marking an increase of 22.00 Cr..
For Expenses, as of Mar 2025, the value is 200.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 194.00 Cr. (Dec 2024) to 200.00 Cr., marking an increase of 6.00 Cr..
For Operating Profit, as of Mar 2025, the value is 140.00 Cr.. The value appears strong and on an upward trend. It has increased from 124.00 Cr. (Dec 2024) to 140.00 Cr., marking an increase of 16.00 Cr..
For OPM %, as of Mar 2025, the value is 41.00%. The value appears strong and on an upward trend. It has increased from 39.00% (Dec 2024) to 41.00%, marking an increase of 2.00%.
For Other Income, as of Mar 2025, the value is 12.00 Cr.. The value appears to be declining and may need further review. It has decreased from 13.00 Cr. (Dec 2024) to 12.00 Cr., marking a decrease of 1.00 Cr..
For Interest, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
For Depreciation, as of Mar 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 5.00 Cr..
For Profit before tax, as of Mar 2025, the value is 147.00 Cr.. The value appears strong and on an upward trend. It has increased from 132.00 Cr. (Dec 2024) to 147.00 Cr., marking an increase of 15.00 Cr..
For Tax %, as of Mar 2025, the value is 25.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 25.00%.
For Net Profit, as of Mar 2025, the value is 110.00 Cr.. The value appears strong and on an upward trend. It has increased from 99.00 Cr. (Dec 2024) to 110.00 Cr., marking an increase of 11.00 Cr..
For EPS in Rs, as of Mar 2025, the value is 6.35. The value appears strong and on an upward trend. It has increased from 5.71 (Dec 2024) to 6.35, marking an increase of 0.64.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
×
Quarterly Chart
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 2:28 pm
Metric
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Sales
538
499
683
721
712
1,030
Expenses
325
292
434
502
482
652
Operating Profit
214
207
249
219
229
378
OPM %
40%
41%
36%
30%
32%
37%
Other Income
6
9
19
24
19
46
Interest
7
5
3
1
0
0
Depreciation
18
20
22
25
28
18
Profit before tax
194
190
243
217
220
406
Tax %
25%
26%
25%
26%
26%
25%
Net Profit
145
142
182
160
164
305
EPS in Rs
24,118.33
1,428.57
10.47
9.23
9.44
17.59
Dividend Payout %
0%
0%
0%
0%
11%
0%
×
Profit & Loss Yearly Chart
YoY Net Profit Growth
Year
2020-2021
2021-2022
2022-2023
2023-2024
2024-2025
YoY Net Profit Growth (%)
-2.07%
28.17%
-12.09%
2.50%
85.98%
Change in YoY Net Profit Growth (%)
0.00%
30.24%
-40.26%
14.59%
83.48%
Blue Jet Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2020-2021 to 2024-2025.
Growth
Compounded Sales Growth
10 Years:
%
5 Years:
14%
3 Years:
15%
TTM:
45%
Compounded Profit Growth
10 Years:
%
5 Years:
16%
3 Years:
19%
TTM:
78%
Stock Price CAGR
10 Years:
%
5 Years:
%
3 Years:
%
1 Year:
109%
Return on Equity
10 Years:
%
5 Years:
31%
3 Years:
27%
Last Year:
31%
Last Updated: Unknown
No data available for the Balance Sheet data table.
After reviewing the key financial ratios for Blue Jet Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
For FaceValue, as of Mar 21, the value is 100.00. This value exceeds the healthy maximum of 10. There is no change compared to the previous period (Mar 20) which recorded 100.00.
For Basic EPS (Rs.), as of Mar 21, the value is 1,396.27. This value is within the healthy range. It has decreased from 1,462.59 (Mar 20) to 1,396.27, marking a decrease of 66.32.
For Diluted EPS (Rs.), as of Mar 21, the value is 1,396.27. This value is within the healthy range. It has decreased from 1,462.59 (Mar 20) to 1,396.27, marking a decrease of 66.32.
For Cash EPS (Rs.), as of Mar 21, the value is 1,568.30. This value is within the healthy range. It has decreased from 27,166.33 (Mar 20) to 1,568.30, marking a decrease of 25,598.03.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 21, the value is 3,428.34. It has decreased from 32,238.33 (Mar 20) to 3,428.34, marking a decrease of 28,809.99.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 21, the value is 3,428.34. It has decreased from 32,238.33 (Mar 20) to 3,428.34, marking a decrease of 28,809.99.
For Revenue From Operations / Share (Rs.), as of Mar 21, the value is 5,033.61. It has decreased from 89,699.16 (Mar 20) to 5,033.61, marking a decrease of 84,665.55.
For PBDIT / Share (Rs.), as of Mar 21, the value is 2,168.43. This value is within the healthy range. It has decreased from 36,589.16 (Mar 20) to 2,168.43, marking a decrease of 34,420.73.
For PBIT / Share (Rs.), as of Mar 21, the value is 1,970.05. This value is within the healthy range. It has decreased from 33,582.66 (Mar 20) to 1,970.05, marking a decrease of 31,612.61.
For PBT / Share (Rs.), as of Mar 21, the value is 1,862.96. This value is within the healthy range. It has decreased from 32,354.50 (Mar 20) to 1,862.96, marking a decrease of 30,491.54.
For Net Profit / Share (Rs.), as of Mar 21, the value is 1,369.92. This value is within the healthy range. It has decreased from 24,159.83 (Mar 20) to 1,369.92, marking a decrease of 22,789.91.
For NP After MI And SOA / Share (Rs.), as of Mar 21, the value is 1,396.43. This value is within the healthy range. It has decreased from 24,141.33 (Mar 20) to 1,396.43, marking a decrease of 22,744.90.
For PBDIT Margin (%), as of Mar 21, the value is 43.07. This value is within the healthy range. It has increased from 40.79 (Mar 20) to 43.07, marking an increase of 2.28.
For PBIT Margin (%), as of Mar 21, the value is 39.13. This value exceeds the healthy maximum of 20. It has increased from 37.43 (Mar 20) to 39.13, marking an increase of 1.70.
For PBT Margin (%), as of Mar 21, the value is 37.01. This value is within the healthy range. It has increased from 36.07 (Mar 20) to 37.01, marking an increase of 0.94.
For Net Profit Margin (%), as of Mar 21, the value is 27.21. This value exceeds the healthy maximum of 10. It has increased from 26.93 (Mar 20) to 27.21, marking an increase of 0.28.
For NP After MI And SOA Margin (%), as of Mar 21, the value is 27.74. This value exceeds the healthy maximum of 20. It has increased from 26.91 (Mar 20) to 27.74, marking an increase of 0.83.
For Return on Networth / Equity (%), as of Mar 21, the value is 40.73. This value is within the healthy range. It has decreased from 75.40 (Mar 20) to 40.73, marking a decrease of 34.67.
For Return on Capital Employeed (%), as of Mar 21, the value is 52.32. This value is within the healthy range. It has decreased from 83.21 (Mar 20) to 52.32, marking a decrease of 30.89.
For Return On Assets (%), as of Mar 21, the value is 25.94. This value is within the healthy range. It has decreased from 38.58 (Mar 20) to 25.94, marking a decrease of 12.64.
For Long Term Debt / Equity (X), as of Mar 21, the value is 0.08. This value is below the healthy minimum of 0.2. It has decreased from 0.19 (Mar 20) to 0.08, marking a decrease of 0.11.
For Total Debt / Equity (X), as of Mar 21, the value is 0.10. This value is within the healthy range. It has decreased from 0.30 (Mar 20) to 0.10, marking a decrease of 0.20.
For Asset Turnover Ratio (%), as of Mar 21, the value is 1.10. It has increased from 0.00 (Mar 20) to 1.10, marking an increase of 1.10.
For Current Ratio (X), as of Mar 21, the value is 2.43. This value is within the healthy range. It has increased from 1.89 (Mar 20) to 2.43, marking an increase of 0.54.
For Quick Ratio (X), as of Mar 21, the value is 1.69. This value is within the healthy range. It has increased from 1.37 (Mar 20) to 1.69, marking an increase of 0.32.
For Inventory Turnover Ratio (X), as of Mar 21, the value is 2.30. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 20) to 2.30, marking an increase of 2.30.
For Interest Coverage Ratio (X), as of Mar 21, the value is 40.49. This value is within the healthy range. It has increased from 29.79 (Mar 20) to 40.49, marking an increase of 10.70.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 21, the value is 27.58. This value is within the healthy range. It has increased from 20.67 (Mar 20) to 27.58, marking an increase of 6.91.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
×
Profitability Ratios (%)
Liquidity Ratios
Liquidity Ratios (%)
Interest Coverage Ratios (%)
Valuation Ratios
Fair Value
Fair Value of Blue Jet Healthcare Ltd as of June 26, 2025 is: 807.07
Calculation basis:
Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.
As of June 26, 2025, Blue Jet Healthcare Ltd is Overvalued by 8.50% compared to the current share price 882.00
Intrinsic Value of Blue Jet Healthcare Ltd as of June 26, 2025 is: 918.84
Calculation basis:
Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.
This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.
As of June 26, 2025, Blue Jet Healthcare Ltd is Undervalued by 4.18% compared to the current share price 882.00
Last 5 Year EPS CAGR: 13.85%
*Investments are subject to market risks
Strength and Weakness
Unable to fetch valid data for stock valuation.
Stock Analysis
Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Blue Jet Healthcare Ltd:
Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
ROE%: 40.73% (Industry Average ROE: 15.19%)
ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
Stock P/E: 50.1 (Industry average Stock P/E: 103.22)
Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
Total Debt / Equity: 0.1
Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions. Stock Rating:
About the Company - Qualitative Analysis
Blue Jet Healthcare Ltd is a Public Limited Listed company incorporated on 07/12/1968 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L99999MH1968PLC014154 and registration number is 014154. Currently Company is involved in the business activities of Manufacture of other pharmaceutical and botanical products like hina powder etc.. Company's Total Operating Revenue is Rs. 1029.99 Cr. and Equity Capital is Rs. 34.69 Cr. for the Year ended 31/03/2025.
FAQ: Stock data is invalid or not in the correct format.
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Blue Jet Healthcare Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
